National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study.

ABSTRACT:

Background

Currently available live, oral rotavirus vaccines (LORVs) have significantly reduced severe rotavirus hospitalizations and deaths worldwide. However, LORVs are not as effective in low- and middle-income countries (LMIC) where rotavirus disease burden is highest. Next-generation rotavirus vaccine (NGRV) candidates in development may have a greater public health impact where they are needed most. The feasibility and acceptability of possible new rotavirus vaccines were explored as part of a larger public health value proposition for injectable NGRVs in LMICs.

Objective

To assess national stakeholder preferences for currently available LORVs and hypothetical NGRVs and understand rationales and drivers for stated preferences.

Methods

Interviews were conducted w

SUBMITTER: Price J 

PROVIDER: S-EPMC8767494 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature